Phurpa Wangchuk

Prof. Phurpa Wangchuk

James Cook University, Australia, Townsville, Australia
+1
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2022 in Molecules
Verified
Journal Article
Open access
PDF file
KYKarma Yeshi
Karma Yeshi
DCDarren Crayn
Darren Crayn
EREdita Ritmejerytė
Edita Ritmejerytė
Phurpa WangchukPhurpa Wangchuk
Phurpa Wangchuk
Plant secondary metabolites (PSMs) are vital for human health and constitute the skeletal framework of many pharmaceutical drugs. Indeed, more than 25% of the existing drugs belong to PSMs. One of the continuing challenges for drug discovery and pharmaceutical industries is gaining access to natural products, including medicinal plants. This bottleneck is heightened for endangered species prohibited for large sample collection, even if they show biological hits. While cultivating the pharmaceutically interesting plant species may be a solution, it is not always possible to grow the organism outside its natural habitat. Plants affected by abiotic stress present a potential alternative source for drug discovery. In order to overcome abiotic environmental stressors, plants may mount a defense response by producing a diversity of PSMs to avoid cells and tissue damage. Plants either synthesize new chemicals or increase the concentration (in most instances) of existing chemicals, including the prominent bioactive lead compounds morphine, camptothecin, catharanthine, epicatechin-3-gallate (EGCG), quercetin, resveratrol, and kaempferol. Most PSMs produced under various abiotic stress conditions are plant defense chemicals and are functionally anti-inflammatory and antioxidative. The major PSM groups are terpenoids, followed by alkaloids and phenolic compounds. We have searched the literature on plants affected by abiotic stress (primarily studied in the simulated growth conditions) and their PSMs (including pharmacological activities) from PubMed, Scopus, MEDLINE Ovid, Google Scholar, Databases, and journal websites. We used search keywords: “stress-affected plants,” “plant secondary metabolites, “abiotic stress,” “climatic influence,” “pharmacological activities,” “bioactive compounds,” “drug discovery,” and “medicinal plants” and retrieved published literature between 1973 to 2021. This review provides an overview of variation in bioactive phytochemical production in plants under various abiotic stress and their potential in the biodiscovery of therapeutic drugs. We excluded studies on the effects of biotic stress on PSMs.

10 September 2024 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
Phurpa WangchukPhurpa Wangchuk
Phurpa Wangchuk
KYKarma Yeshi
Karma Yeshi
ALAlex Loukas
Alex Loukas

28 April 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KYKarma Yeshi
Karma Yeshi
RRRoland Ruscher
Roland Ruscher
LHLuke Hunter
Luke Hunter
NDNorelle Daly
Norelle Daly
Alex LoukasAlex Loukas
Alex Loukas
Phurpa WangchukPhurpa Wangchuk
Phurpa Wangchuk
Inflammatory bowel disease (IBD) is a chronic and life-long disease characterized by gastrointestinal tract inflammation. It is caused by the interplay of the host’s genetic predisposition and immune responses, and various environmental factors. Despite many treatment options, there is no cure for IBD. The increasing incidence and prevalence of IBD and lack of effective long-term treatment options have resulted in a substantial economic burden to the healthcare system worldwide. Biologics targeting inflammatory cytokines initiated a shift from symptomatic control towards objective treatment goals such as mucosal healing. There are seven monoclonal antibody therapies excluding their biosimilars approved by the US Food and Drug Administration for induction and maintenance of clinical remission in IBD. Adverse side effects associated with almost all currently available drugs, especially biologics, is the main challenge in IBD management. Natural products have significant potential as therapeutic agents with an increasing role in health care. Given that natural products display great structural diversity and are relatively easy to modify chemically, they represent ideal scaffolds upon which to generate novel therapeutics. This review focuses on the pathology, currently available treatment options for IBD and associated challenges, and the roles played by natural products in health care. It discusses these natural products within the current biodiscovery research agenda, including the applications of drug discovery techniques and the search for next-generation drugs to treat a plethora of inflammatory diseases, with a major focus on IBD.

21 January 2018 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
RERamon Eichenberger
Ramon Eichenberger
MTMD Hasanuzzaman TALUKDER
MD Hasanuzzaman TALUKDER
MFMatthew Field
Matthew Field
Phurpa WangchukPhurpa Wangchuk
Phurpa Wangchuk
PGPaul Giacomin
Paul Giacomin
JSJavier Sotillo
Javier Sotillo
Whipworms are parasitic nematodes that live in the gut of more than 500 million people worldwide. Owing to the difficulty in obtaining parasite material, the mouse whipworm Trichuris muris has been extensively used as a model to study human whipworm infections. These nematodes secrete a multitude of compounds that interact with host tissues where they orchestrate a parasitic existence. Herein we provide the first comprehensive characterization of the excretory/secretory products of T. muris. We identify 148 proteins secreted by T. muris and show for the first time that the mouse whipworm secretes exosome‐like extracellular vesicles (EVs) that can interact with host cells. We use an Optiprep® gradient to purify the EVs, highlighting the suitability of this method for purifying EVs secreted by a parasitic nematode. We also characterize the proteomic and genomic content of the EVs, identifying >350 proteins, 56 miRNAs (22 novel) and 475 full‐length mRNA transcripts mapping to T. muris gene models. Many of the miRNAs putatively mapped to mouse genes are involved in regulation of inflammation, implying a role in parasite‐driven immunomodulation. In addition, for the first time to our knowledge, colonic organoids have been used to demonstrate the internalization of parasite EVs by host cells. Understanding how parasites interact with their host is crucial to develop new control measures. This first characterization of the proteins and EVs secreted by T. muris provides important information on whipworm–host communication and forms the basis for future studies.

3 December 2019 in Molecules
Verified
Journal Article
Open access
PDF file
ANAri Nugraha
Ari Nugraha
YDYuvita Dian Damayanti
Yuvita Dian Damayanti
Phurpa WangchukPhurpa Wangchuk
Phurpa Wangchuk
PKPaul Keller
Paul Keller
Annona species have been a valuable source of anti-infective and anticancer agents. However, only limited evaluations of their alkaloids have been carried out. This review collates and evaluates the biological data from extracts and purified isolates for their anti-infective and anti-cancer activities. An isoquinoline backbone is a major structural alkaloid moiety of the Annona genus, and more than 83 alkaloids have been isolated from this genus alone. Crude extracts of Annona genus are reported with moderate activities against Plasmodium falciparum showing larvicidal activities. However, no pure compounds from the Annona genus were tested against the parasite. The methanol extract of Annona muricata showed apparent antimicrobial activities. The isolated alkaloids from this genus including liriodenine, anonaine, asimilobine showed sensitivity against Staphylococcus epidermidis. Other alkaloids such as (+)-Xylopine and isocoreximine indicated significant anti-cancer activity against A549 and K-562 cell lines, respectively. This review revealed that the alkaloids from Annona genus are rich in structural diversity and pharmacological activities. Further exploration of this genus and their alkaloids has potential for developing novel anti-infective and anticancer drugs.

1 September 2011 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
Phurpa WangchukPhurpa Wangchuk
Phurpa Wangchuk
PKPaul Keller
Paul Keller
SPStephen Pyne
Stephen Pyne
MTMalai Taweechotipatr
Malai Taweechotipatr
ATAunchalee Tonsomboon
Aunchalee Tonsomboon
SKSumalee Kamchonwongpaisan
Sumalee Kamchonwongpaisan